Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 2
1980 5
1981 8
1982 37
1983 17
1984 26
1985 19
1986 23
1987 29
1988 32
1989 39
1990 39
1991 59
1992 74
1993 77
1994 103
1995 129
1996 109
1997 143
1998 215
1999 222
2000 206
2001 225
2002 243
2003 242
2004 234
2005 267
2006 231
2007 249
2008 257
2009 251
2010 256
2011 266
2012 278
2013 235
2014 280
2015 289
2016 289
2017 298
2018 308
2019 292
2020 253
Text availability
Article attribute
Article type
Publication date

Search Results

6,369 results
Results by year
Filters applied: . Clear all
Page 1
Reviewing the therapeutic role of budesonide in Crohn's disease.
López-Sanromán A, Clofent J, Garcia-Planella E, Menchén L, Nos P, Rodríguez-Lago I, Domènech E. López-Sanromán A, et al. Gastroenterol Hepatol. 2018 Aug-Sep;41(7):458-471. doi: 10.1016/j.gastrohep.2018.05.013. Epub 2018 Jul 12. Gastroenterol Hepatol. 2018. PMID: 30007787 Free article. Review. English, Spanish.
Oral budesonide is a glucocorticoid of primarily local action. In the field of digestive diseases, it is used mainly in inflammatory bowel disease, but also in other indications. This review addresses the pharmacology, pharmacodynamics and therapeutic use of budesonide
Oral budesonide is a glucocorticoid of primarily local action. In the field of digestive diseases, it is used mainly in inflammatory …
Benefit:Risk Profile of Budesonide in Obstructive Airways Disease.
Tashkin DP, Lipworth B, Brattsand R. Tashkin DP, et al. Drugs. 2019 Nov;79(16):1757-1775. doi: 10.1007/s40265-019-01198-7. Drugs. 2019. PMID: 31549299 Free PMC article. Review.
Inhaled budesonide's physiochemical and pharmacokinetic/pharmacodynamic properties allow it to reach a rapid and high airway efficacy due to its more balanced relationship between water solubility and lipophilicity. ...Budesonide remains one of the most well- …
Inhaled budesonide's physiochemical and pharmacokinetic/pharmacodynamic properties allow it to reach a rapid and high airway e …
Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials.
Bafadhel M, Peterson S, De Blas MA, Calverley PM, Rennard SI, Richter K, Fagerås M. Bafadhel M, et al. Lancet Respir Med. 2018 Feb;6(2):117-126. doi: 10.1016/S2213-2600(18)30006-7. Epub 2018 Jan 10. Lancet Respir Med. 2018. PMID: 29331313 Clinical Trial.
METHODS: We analysed data from three AstraZeneca randomised controlled trials of budesonide-formoterol in patients with COPD with a history of exacerbations and available blood eosinophil counts. ...Interactions were observed between eosinophil count and the treatment effe …
METHODS: We analysed data from three AstraZeneca randomised controlled trials of budesonide-formoterol in patients with COPD with a h …
Editorial.
Toskala E. Toskala E. Int Forum Allergy Rhinol. 2017 May;7(5):439-440. doi: 10.1002/alr.21947. Int Forum Allergy Rhinol. 2017. PMID: 28493305 No abstract available.
Efficacy of inhaled budesonide for the treatment of severe equine asthma.
Lavoie JP, Leclere M, Rodrigues N, Lemos KR, Bourzac C, Lefebvre-Lavoie J, Beauchamp G, Albrecht B. Lavoie JP, et al. Equine Vet J. 2019 May;51(3):401-407. doi: 10.1111/evj.13018. Epub 2018 Sep 25. Equine Vet J. 2019. PMID: 30203854 Free PMC article. Clinical Trial.
RESULTS: In Study 1, there was a marked and significant improvement in the lung function of all horses treated with budesonide and dexamethasone. Neutrophil percentages in bronchoalveolar fluid decreased in all horses treated with dexamethasone and in four of six horses tr …
RESULTS: In Study 1, there was a marked and significant improvement in the lung function of all horses treated with budesonide and de …
The SYGMA programme of phase 3 trials to evaluate the efficacy and safety of budesonide/formoterol given 'as needed' in mild asthma: study protocols for two randomised controlled trials.
O'Byrne PM, FitzGerald JM, Zhong N, Bateman E, Barnes PJ, Keen C, Almqvist G, Pemberton K, Jorup C, Ivanov S, Reddel HK. O'Byrne PM, et al. Trials. 2017 Jan 10;18(1):12. doi: 10.1186/s13063-016-1731-4. Trials. 2017. PMID: 28069068 Free PMC article. Clinical Trial.
SYGMA2 aims to recruit 4114 patients who will be randomised to placebo bid plus as-needed budesonide/formoterol 160/4.5 μg, or budesonide 200 μg bid plus as-needed terbutaline 0.4 mg. The primary objective is to demonstrate the noninferiority of as-needed budeson
SYGMA2 aims to recruit 4114 patients who will be randomised to placebo bid plus as-needed budesonide/formoterol 160/4.5 μg, or bud
Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease.
Edsbäcker S, Andersson T. Edsbäcker S, et al. Clin Pharmacokinet. 2004;43(12):803-21. doi: 10.2165/00003088-200443120-00003. Clin Pharmacokinet. 2004. PMID: 15355126 Review.
This overview summarises available pharmacokinetic data on budesonide capsules (Entocort EC), approved for the treatment of mild-to-moderate active Crohn's disease involving the ileum and/or ascending colon and for prolongation of symptom control. ...In summary, …
This overview summarises available pharmacokinetic data on budesonide capsules (Entocort EC), approved for the treatment of mild-to-m …
Efficacy and safety of budesonide/formoterol pMDI vs budesonide pMDI in asthmatic children (6-<12 years).
Pearlman DS, Eckerwall G, McLaren J, Lamarca R, Puu M, Gilbert I, Jorup C, Sandin K, Lanz MJ. Pearlman DS, et al. Ann Allergy Asthma Immunol. 2017 Apr;118(4):489-499.e1. doi: 10.1016/j.anai.2017.01.020. Epub 2017 Mar 1. Ann Allergy Asthma Immunol. 2017. PMID: 28256307 Free article. Clinical Trial.
OBJECTIVE: To evaluate the efficacy of 2 formoterol doses added to budesonide as fixed combinations vs budesonide alone in children 6 to younger than 12 years with asthma. ...Children symptomatic during a 7-28-day run-in on low-dose ICS, 1 inhalation of budesonid
OBJECTIVE: To evaluate the efficacy of 2 formoterol doses added to budesonide as fixed combinations vs budesonide alone in chi …
Biophysical and chemical stability of surfactant/budesonide and the pulmonary distribution following intra-tracheal administration.
Chen CM, Chang CH, Chao CH, Wang MH, Yeh TF. Chen CM, et al. Drug Deliv. 2019 Dec;26(1):604-611. doi: 10.1080/10717544.2019.1618418. Drug Deliv. 2019. PMID: 31204848 Free PMC article.
Chemical stability of Survanta/budesonide and of Curosurf/budesonide suspensions was tested by high-performance liquid chromatography analysis (HPLC). ...Both surfactants can act as an effective vehicle for budesonide delivery....
Chemical stability of Survanta/budesonide and of Curosurf/budesonide suspensions was tested by high-performance liquid chromat …
Treatment of oral mucosal manifestations of chronic graft-versus-host disease: dexamethasone vs. budesonide.
Zadik Y, Elad S, Shapira A, Shapira MY. Zadik Y, et al. Expert Opin Pharmacother. 2017 Feb;18(3):235-242. doi: 10.1080/14656566.2017.1282464. Epub 2017 Jan 25. Expert Opin Pharmacother. 2017. PMID: 28081677 Review.
Oral mucosal cGVHD markedly affect individual's daily function and wellbeing. In some cases, it might become a life threating complication. ...Budesonide's pharmacological characteristics mark it as a preferable topical agent for oral cGVHD....
Oral mucosal cGVHD markedly affect individual's daily function and wellbeing. In some cases, it might become a life threating complic …
6,369 results
Jump to page
Feedback